Characterization of Ribavirin Aerosol With Small Particle Aerosol Generator and Vibrating Mesh Micropump Aerosol Technologies

References

1. 1.↵
   1. Chu HY,
   2. Englund JA

   . Respiratory syncytial virus disease: prevention and treatment. Curr Top Microbiol Immunol 2013;372:235–258.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Ventre K,
   2. Randolph AG

   . Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2007;(1):CD000181.
3. 3.↵
   1. Neemann K,
   2. Freifeld A

   . Respiratory syncytial virus in hematopoietic stem cell transplantation and solid-organ transplantation. Curr Infect Dis Rep 2015;17(7):490.

   OpenUrlPubMed
4. 4.↵
   1. Shah DP,
   2. Ghantoji SS,
   3. Shah JN,
   4. El Taoum KK,
   5. Jiang Y,
   6. Popat U,
   7. et al

   . Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 2013;68(8):1872–1880.

   OpenUrlAbstract/FREE Full Text
5. 5.
   1. Fätkenheuer G,
   2. Gillor D,
   3. Platten M,
   4. Kochanek M,
   5. Salzberger B

   . Aerosolized ribavirin for patients with cancer and respiratory syncytial virus infection. J Infect Dis 2013;207(10):1621.

   OpenUrlFREE Full Text
6. 6.
   1. Seo S,
   2. Campbell AP,
   3. Xie H,
   4. Chien JW,
   5. Leisenring WM,
   6. Englund JA,
   7. Boeckh M

   . Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant 2013;19(4):589–596.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Chemaly RF,
   2. Torres HA,
   3. Munsell MF,
   4. Shah DP,
   5. Rathod DB,
   6. Bodey GP,
   7. et al

   . An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis 2012;206(9):1367–1371.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Gilbert BE,
   2. Knight V

   . Biochemistry and clinical applications of ribavirin: antimicrobial agents and chemotherapy 1986;30(2):201–205.
9. 9.↵
   1. Englund JA,
   2. Piedra PA,
   3. Jefferson LS,
   4. Wilson SZ,
   5. Taber LH,
   6. Gilbert BE

   . High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J Pediatr 1990;117(2 Pt 1):313–320.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Smith DW,
    2. Frankel LR,
    3. Mathers LH,
    4. Tang AT,
    5. Ariagno RL,
    6. Prober CG

    . A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991;325(1):24–29.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Newth CJ,
    2. Clark AR

    . In vitro performance of the small particle aerosol generator (SPAG-2). Pediatr Pulmonol 1989;7(3):183–188.

    OpenUrlPubMed
12. 12.↵
    1. Waldrep JC,
    2. Dhand R

    . Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr Drug Deliv 2008;5(2):114–119.

    OpenUrlCrossRefPubMed
13. 13.
    1. Zhang G,
    2. David A,
    3. Wiedmann TS

    . Performance of the vibrating membrane aerosol generation device: Aeroneb Micropump Nebulizer. J Aerosol Med 2007;20(4):408–416.

    OpenUrlPubMed
14. 14.
    1. Golshahi L,
    2. Longest PW,
    3. Azimi M,
    4. Syed A,
    5. Hindle M

    . Intermittent aerosol delivery to the lungs during high-flow nasal cannula therapy. Respir Care 2014;59(10):1476–1486.

    OpenUrlAbstract/FREE Full Text
15. 15.
    1. Perry SA,
    2. Kesser KC,
    3. Geller DE,
    4. Selhorst DM,
    5. Rendle JK,
    6. Hertzog JH

    . Influences of cannula size and flow rate on aerosol drug delivery through the Vapotherm humidified high-flow nasal cannula system. Pediatr Crit Care Med 2013;14(5):e250–e256.

    OpenUrlPubMed
16. 16.↵
    1. Ari A,
    2. Harwood R,
    3. Sheard M,
    4. Dailey P,
    5. Fink JB

    . In vitro comparison of heliox and oxygen in aerosol delivery using pediatric high flow nasal cannula. Pediatr Pulmonol 2011;46(8):795–801.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Sidler-Moix AL,
    2. Di Paolo ER,
    3. Dolci U,
    4. Berger-Gryllaki M,
    5. Cotting J,
    6. Pannatier A

    . Physicochemical aspects and efficiency of albuterol nebulization: comparison of three aerosol types in an in vitro pediatric model. Respir Care 2015;60(1):38–46.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    Standardization IOf. Anaesthetic and respiratory equipment: nebulizing systems and components
19. 19.↵
    1. Molinos-Quintana A,
    2. Pérez-de Soto C,
    3. Gómez-Rosa M,
    4. Pérez-Simon JA,
    5. Pérez-Hurtado JM

    . Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients. Bone Marrow Transplant 2013;48(2):265–268.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Gueller S,
    2. Duenzinger U,
    3. Wolf T,
    4. Ajib S,
    5. Mousset S,
    6. Berger A,
    7. et al

    . Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 2013;15(4):435–440.

    OpenUrlCrossRefPubMed